Hoofddorp, the Netherlands, 14 July 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream – a risk factor associated with Alzheimer’s disease – through a first-of-its-kind in-home blood test and a dietary supplement for those with elevated free copper levels.

Continue reading →